Výsledky vyhledávání - "Nickelsen, T"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene

Autor: Ettinger, B., Black, D.M., Mitlak, B.H., Knickerbocker, R.K., Nickelsen, T., Genant, H.K., Christiansen, C., Delmas, P.D., Zanchetta, J.R., Stakkestad, J., Gluer, C.C., Krueger, B.P., Cohen, F.J., Eckert, S., Ensrud, K.E., Avioli, L.V., Lips, P.T.A.M., Cummings, S.R.

Publikováno v: Ettinger, B, Black, D M, Mitlak, B H, Knickerbocker, R K, Nickelsen, T, Genant, H K, Christiansen, C, Delmas, P D, Zanchetta, J R, Stakkestad, J, Gluer, C C, Krueger, B P, Cohen, F J, Eckert, S, Ensrud, K E, Avioli, L V, Lips, P T A M & Cummings, S R 1999, ' Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene ', JAMA, vol. 282, pp. 637-645 . https://doi.org/10.1001/jama.282.7.637
JAMA, 282, 637-645. American Medical Association

Context: Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known. Objective: To determine the effect of raloxifene therapy on risk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::2cd68432022ffecb03ffdf3a3394de6a
https://doi.org/10.1001/jama.282.7.637

Zobrazit plný text záznamu

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide

Autor: Blumsohn, A., Marin, F., Nickelsen, T., Brixen, K., Sigurdsson, G., de la Vera, J. G., Boonen, S., Liu-Leage, S., Barker, C., Eastell, R., EUROFORS Study Grp, ESG

Summary\ud \ud We report the changes in biochemical markers of bone formation during the first 6 months of teriparatide therapy in postmenopausal women with osteoporosis according to previous antiresorptive treatment. Prior therapy does not adversely

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::22d4eb92acd871cb57486acd4628f77d

Zobrazit plný text záznamu

Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women

Autor: Ringe, J. D. Christodoulakos, G. E. Mellstroem, D. Petto, H. and Nickelsen, T. Marin, F. Pavo, I.

Objectives: The aim was to investigate patient compliance with different osteoporosis medications commonly prescribed in clinical practice, to determine risk factors associated with discontinuation and to evaluate quality of changes. Research design

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::d1d3dfafec0239c7b2951cdda657fc3d
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3118294

Zobrazit plný text záznamu

Comparison of 3 sequential treatment regimens of teriparatide: Final results from the EUROFORS study

Autor: Eastell, R, Hadji, P, Farrerons, J, Audran, M, Boonen, S, Brixen, Kim, Melo Gomes, J, Obermayer-Pietsch, B, Avramidis, A, Sigurdsson, G, Glüer, C, Cleall, S, Marin, F, Nickelsen, T

Publikováno v: Eastell, R, Hadji, P, Farrerons, J, Audran, M, Boonen, S, Brixen, K, Melo Gomes, J, Obermayer-Pietsch, B, Avramidis, A, Sigurdsson, G, Glüer, C, Cleall, S, Marin, F & Nickelsen, T 2006, Comparison of 3 sequential treatment regimens of teriparatide: Final results from the EUROFORS study . in Journal of Bone and Mineral Research . vol. 21 suppl 1, pp. S70-S70, Annual meeting of the American Society for Bone and Mineral Research, United States, 24/08/2010 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::5d593a1a6d8b3c10d22a26c57f97cf45
https://portal.findresearcher.sdu.dk/da/publications/1384b2a0-d07b-11db-bc51-000ea68e967b

Zobrazit plný text záznamu

Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1

Autor: Neven, P. Quail, D. Marin, F. Creatsas, G. Depypere, H. Rechberger, T. Liu-Léage, S. Pavo, I. Schmitt, H. Nickelsen, T.

Objectives: To review the main findings of the Euralox 1 study - a multicentre, randomised, double-blind study conducted in 1008 healthy postmenopausal women allocated to raloxifene (n = 495) or continuous combined estrogen-progestin therapy (ccEPT;

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::7a43409ec177a1d8e296ea10b41748ec
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3095472

Zobrazit plný text záznamu

Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: Results from the Euralox I study

Autor: Nickelsen, T. Creatsas, G. Rechberger, T. Depypere, H. Erenus, M. Quail, D. Arndt, T. Bonnar, J.

Objective: To compare the effects of the selective estrogen receptor modulator (SERM) raloxifene (Evista®) and a continuous combined hormone replacement therapy (ccHRT) formulation containing estradiol and norethisterone acetate (Kliogest®) on lipi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::7805780364749a10f1ec27571d9ebdec
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3133831

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání